🇺🇸 FDA
Patent

US 12091386

D-amphetamine compounds, compositions, and processes for making and using the same

granted A61KA61K31/4458A61K31/4545

Quick answer

US patent 12091386 (D-amphetamine compounds, compositions, and processes for making and using the same) held by Zevra Therapeutics, Inc. expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Zevra Therapeutics, Inc.
Grant date
Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/4458, A61K31/4545, A61K47/55, A61K9/0019